American Society of Clinical Oncology. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2025 American Society of Clinical Oncology ...

Fig 1.Management of the axilla for patients with clinical T ≤2 cm breast cancer. a Multidisciplinary discussion of adjuvant therapy options should occur prior to surgery when omitting sentinel lymph ...

Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic ...

Background: Currently, there is no universally accepted first line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and an unmet medical need ...

Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a ...

Background: RC48-ADC is a novel humanized anti-HER2 antibody-drug conjugate (ADC), which showed promising data in HER2-positive and even negative patients (pts) with metastatic urothelial carcinoma ...

Worldwide, bladder cancer is the ninth most common malignancy, and the sixth most common in the United States. 1-3 Despite recent therapeutic advances, clinical outcomes in more advanced settings ...

Most patients with pancreatic adenocarcinoma present with advanced disease at diagnosis, 1 which remains difficult to treat. With 5-year survival rates between 8% and 13%, 1,2 prognosis for patients ...

Concern about the well-being, professional fulfillment, and capacity of the oncology workforce has been rising, especially following the COVID-19 pandemic. 1 ASCO identified the oncology profession as ...

Nonmutational p53 dysfunction identifies MDS with poor outcomes that are not efficiently captured by conventional prognostic scores. These patients typically display (1) abnormal p53 protein ...

CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease This scoping review was conducted based on the Arksey and O'Malley framework and the work of Levac et al. The databases searched ...

Until recently, the mainstay of systemic treatment of pancreatic cancer has been chemotherapy. 1,2 The first treatment to be approved for advanced pancreatic cancer was gemcitabine, which was tested ...